2010 Fiscal Year Final Research Report
Pretreatment of human mesenchymal stem cells with HMG-CoA reductase inhibitor improved efficiency of cardiomyogenic transdifferentiation
| Project/Area Number |
21790158
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Keywords | 骨髄間葉系細胞 / スタチン / 心筋誘導 |
|---|
| Research Abstract |
In this study, our challenge was to improve the efficacy of mesenchymal stem cell (MSC)transplantation in vivo by pretreatment of MSCs with HMG-CoA reductase inhibitor. After cardiomyogenic induction in vitro, preteatment with HMG-CoA reductase inhibitor significantly increased the cardio- myogenic transdifferentiation ef ficiency (CTE), which was calculated by immunocytochemistry using anti-cardiac troponin- I antibody. CTE was reduced by pretreatment with HMG-CoA reductase inhibitor and wortmannin, inhibitor of Akt.
|
